ALFA Filings
Every announcement, straight from the exchange
Every Piramal Pharma results update announcement on NSE and BSE, newest first, each with its own page.
Time
3 announcements with these filters
Piramal Pharma released its Q2/H1 FY27 press release reporting revenue of Rs. 2,617 crore for Q2 and Rs. 4,887 crore for H1, with EBITDA up 72%. The filing also upgrades FY27 revenue growth guidance to 19–20%.
Piramal Pharma Limited reported a consolidated revenue of ₹2,270 Crore for Q1 FY27, marking a 17% YoY increase. EBITDA for the quarter rose by 72% to ₹285 Crore.
Piramal Pharma Limited announced its FY26 results, reporting revenue of ₹8,869 Crore. Performance was impacted by inventory destocking and slower inflows, although the company maintained a strong quality track record with zero OAI. Management remains optimistic for FY27 growth driven by the CDMO and CHG businesses.